NFKB2 and plasma cell myeloma: Mutations that activate NF-κB2 signaling including inactivating mutation in TRAF2, TRAF3, cIAP1, and cIAP2, as well as activating mutations or duplications of NIK and NF-κB2 have been identified in patients with multiple myeloma.